USD10
DNTH Shares
About Dianthus TherapeuticsDianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
USD10
DNTH Shares
About Dianthus TherapeuticsDianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$4.08B
OPEN PRICE
$90.21
LOW (1Y)
$13.37
HIGH (1Y)
$57.50
LOW (24H)
$87.40
HIGH (24H)
$94.70
VOLUME (24H)
$753.18K
53.32%
Price history
Time | Price | Change |
|---|---|---|
Today | $90.21 | |
1 Day | $94.34 | 0.00% |
1 Week | $95.34 | |
1 Month | $79.99 | |
1 Year | $18.25 |
Past performance is not a reliable indicator of future results.
Discover more
Popular prediction markets
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.
